NIH launches clinical trial to test antibody treatment in hospitalized COVID-19 patients

(NIH/National Institute of Allergy and Infectious Diseases) Patients admitted with COVID-19 at select hospitals may now volunteer to enroll in a clinical trial to test the safety and efficacy of a potential new treatment for the disease. The Phase 3 randomized, controlled trial, known as ACTIV-3, and as a "master protocol," is designed to expand to test multiple kinds of monoclonal antibody treatments. It also can enroll additional volunteers in the middle of the trial, if a specific investigati...